Welcome to our dedicated page for Coya Therapeutics news (Ticker: COYA), a resource for investors and traders seeking the latest updates and insights on Coya Therapeutics stock.
Coya Therapeutics, Inc. develops investigational biologics intended to enhance regulatory T-cell, or Treg, function in neurodegenerative disorders. Company news centers on COYA 302, including clinical and regulatory updates in amyotrophic lateral sclerosis and frontotemporal dementia, biomarker publications, and research on systemic inflammation, lipid peroxidation, axonal injury, and Treg dysfunction.
Coya updates also cover its Treg-focused therapeutic platforms, including Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Recurring business developments include collaboration activity with Dr. Reddy’s Laboratories, milestone-related revenue disclosures, operating results, stockholder communications, and board or governance changes.
Coya Therapeutics, Inc. (NASDAQ: COYA) has expanded its license agreement with ARScience Biotherapeutics, Inc. to include exclusive worldwide rights for COYA 301, an immunomodulatory cytokine aimed at treating autoimmune and neurodegenerative diseases. This expansion allows Coya to develop COYA 301 as a monotherapy for serious autoimmune diseases in addition to previous rights for neurodegenerative conditions. Coya’s CEO, Howard Berman, emphasizes the potential to address inflammation in a broader patient population. The collaboration aims to advance treatments for conditions characterized by Treg dysfunction and sustained inflammation, leveraging Coya's expertise in Treg-enhancing therapies.
Coya Therapeutics, Inc. (NASDAQ: COYA) has announced plans to present proof-of-concept clinical data from two academic studies on its investigational therapies for Alzheimer’s disease (COYA 301) and Amyotrophic Lateral Sclerosis (ALS) (COYA 302). COYA 301 aims to enhance Treg function in AD patients, with data expected in 1H and 2H 2023. COYA 302 focuses on a biologics combination therapy for ALS, with results to be shared in Q1 2023. Coya, a clinical-stage biotech firm, is leveraging Treg-enhancing therapeutics to address neurodegenerative and autoimmune diseases, emphasizing its commitment to further clinical development.
Coya Therapeutics (NASDAQ: COYA) announced a publication highlighting the potential of expanded human Tregs to suppress neuroinflammation and mitigate Alzheimer's Disease (AD) pathology in a preclinical mice model. The study demonstrated that Treg administration decreased amyloid burden and neuroinflammatory markers, supporting the development of Treg-enhancing therapies as a potential strategy for AD and other neurodegenerative disorders. Coya plans to initiate Phase I clinical trials for these therapies in 2023, with interim data expected by Q1 2024.
Coya Therapeutics, Inc. (Nasdaq: COYA), a clinical-stage biotechnology company, has successfully closed its initial public offering (IPO) of 3,050,000 shares and warrants to purchase additional shares, raising approximately $15.25 million. The shares were sold at $5.00 each, with warrants priced at an exercise fee of $7.50. Trading began on December 29, 2022. Proceeds will primarily support preclinical and clinical trials and various corporate purposes. Underwriters hold an option to purchase 290,000 additional shares to cover over-allotments.
Coya Therapeutics, Inc. (Nasdaq: COYA) announced the pricing of its IPO, offering 3,050,000 shares at $5.00 each, along with warrants to purchase 1,525,000 shares. The IPO is expected to yield approximately $15.25 million in gross proceeds. Net proceeds, after expenses, are projected to be about $13.2 million, intended for advancing clinical trials and corporate purposes. The shares will trade on Nasdaq starting December 29, 2022, and the offering is scheduled to close on January 3, 2023. Joint book-runners include Chardan and Newbridge Securities Corporation.